Chardan Capital Initiates Coverage On CRISPR Therapeutics AG – Common Shares(CRSP). In a research note issued to the investors, the brokerage major Announces the price-target to $23.5 per share. The shares have been rated Buy. The rating by the stock financial advisor at Chardan Capital was issued on Mar 28, 2017 in a research report to their Investors and Clients.
CRISPR Therapeutics AG – Common Shares (CRSP) made into the market gainers list on Fridays trading session with the shares advancing 0.39% or 0.07 points. Due to strong positive momentum, the stock ended at $17.88, which is also near the day’s high of $18.5488. The stock began the session at $17.9 and the volume stood at 48,305 shares. The 52-week high of the shares is $24.9992 and the 52 week low is $11.63. The company has a current market capitalization of $712 M and it has 3,98,10,051 shares in outstanding.